Ardena's drug product manufacturing facility in Somerset Advanced drug product manufacturing facility acquired by Ardena in ...

Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract ...

The takeover also means that a related $11 billion transaction in which Novo Holdings' subsidiary Novo Nordisk takes control of three of Catalent’s fill-and-finish facilities in Italy ...

Novo Nordisk’s majority shareholder Novo Holdings is buying Catalent for $16.5 billion, and then selling the three fill-and-finish facilities in the US, Belgium, and Italy to Novo Nordisk for ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...

Equities research analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Get Free Report) in a report issued on Sunday. The brokerage set a “hold” rating on the stock.

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the ...

By Koba Ryckewaert and Jeanna Smialek Reporting from Brussels Belgium reached an agreement to form a coalition government on Friday, the nation’s monarchy announced, ending seven months of ...

Another one bites the dust. Taste of Belgium is shuttering another location, its seventh closing in the last year. The local restaurant group announced Friday that it will permanently close its ...